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Research in context
Evidence before this study
The pathogenesis of antithyroid drug-induced agranulocytosis has previously been investigated with limited results. Immunological mechanisms such as antibodies to circulating neutrophils and T-cell activation against the blood marrow have been proposed, but the processes are not clearly understood. During the writing of this manuscript, two genome-wide association studies were published describing a strong association between agranulocytosis induced by antithyroid drugs and HLA-B*38:02
and HLA-DRB1*08:03 in ethnic Chinese. The prevalence of these alleles in Europeans is known to be much lower.
Added value of this study
This is the first study describing an association between the HLA region and antithyroid drug-induced agranulocytosis in Europeans. The study is strengthened by bringing together cohorts from four European countries. Notably, the associated HLA types differed between Europeans and the previously studied East-Asians (ethnic Chinese and Japanese). In Europeans, SNPs in a transcriptional repressor and a transcription factor close to HLA were also associated, but linkage disequilibrium (LD) with HLA could contribute to these associations.
Implications of all the available evidence
Agranulocytosis induced by antithyroid drugs is associated with the HLA region on chromosome 6. We have shown that ethnic background determines which genetic variants that need to be tested before the use of these drugs. In Europeans, the predicted probability of antithyroid drug-induced agranulocytosis was 30% and the odds ratio 753 (95% CI [105 -6812]) in heterozygous carriers of three SNPs on chromosome 6. Genotyping of 238 patients offers a means to avoid a potentially lifethreatening adverse drug reaction in one patient by considering alternative treatments or intensified monitoring. Our results represent a further step towards the concept of precision medicine in patients with hyperthyroidism.
Abstract
Background: Drug-induced agranulocytosis is a potentially life-threatening adverse reaction. Genome-wide association studies (GWAS) in ethnic Chinese have shown an association between agranulocytosis induced by antithyroid agents and the human leukocyte antigen (HLA) alleles HLA-B*38:02 and HLA-DRB1*08:03, but this has not been studied in Europeans. Methods: We performed a GWAS on European adults with drug-induced agranulocytosis (n=234, absolute neutrophil count <0•5*10 9 /L (<500/µL)) and population controls (n=5170). Thirty-nine of the agranulocytosis cases were induced by the antithyroid agents thiamazole (methimazole), carbimazole, or propylthiouracil. After imputation and HLA allele prediction, 9380034 single nucleotide polymorphisms (SNPs) and 180 HLA alleles were tested for association. The genomewide significance threshold was p<5*10 -8 . Findings: Overall, drug-induced agranulocytosis was significantly associated with the HLA region on chromosome 6 with odds ratio 3•24 for HLA-B*27:05 (95% CI [2•31, 4 •55] p=1•20*10 -11 ), and 357 for the top SNP rs114291795 (95% CI [2•61, 4 •90] p=2•32*10 -15 ). Drug-specific analysis showed that the association with HLA-B* 27 
Introduction
Serious adverse drug reactions (ADRs) such as drug-induced agranulocytosis can severely limit the use of a drug. Agranulocytosis is defined as a decline in absolute neutrophil count to <0•5x10 9 /L (<500/µL). 1 It is causally related to over 125 nonchemotherapy drugs, and among the most well-documented are thiourea drugs thiamazole (methimazole), carbimazole and propylthiouracil used for the treatment of hyperthyroidism. 2, 3 The risk of agranulocytosis induced by antithyroid agents is estimated to 02-05%, and onset is typically during the first three months of treatment. 3, 4 Patients often present with symptoms of infection such as fever, chills, and myalgias. 5 Left untreated, sepsis will develop in approximately two-thirds of patients. 6 Despite appropriate management, the mortality rate of agranulocytosis induced by non-chemotherapy drugs is 4-5%. 6 The current understanding of the pathogenic mechanism behind drug-induced agranulocytosis is minimal. Antibodies to circulating neutrophils have been found suggesting an immunological mechanism. 7 Another postulated mechanism is induction of T cell-mediated reactions against the myeloid cell line by oxidative drug metabolites. 7 Recently, an association between antithyroid drug-induced agranulocytosis and the human leukocyte antigen (HLA) alleles HLA-B*38:02 8, 9 and HLA-DRB1*08:03 8 have been discovered in ethnic Chinese in Taiwan and Hong Kong. A similar association with HLA-DRB1*08:03, although not as strong, has previously been suggested in the Japanese. 10 Associations were the strongest for the azole drugs thiamazole (methimazole) and carbimazole, [8] [9] [10] and in one study the association with HLA-B*38:02 was strengthened when cases induced by propylthiouracil were removed. 9 To enable genome-wide association studies (GWAS) of this rare condition in Europe, we formed the European Drug-induced Agranulocytosis Consortium (EuDAC). We here present the overall results for all drugs and focus in particular on antithyroid agents.
Methods

Ethical statement
The study was approved by the local ethics committees (2010/231, Uppsala, Sweden; 
Sample description
EuDAC consists of a network of investigators in Sweden, Spain, France and Germany.
The basis for case recruitment in Sweden and France was through nation-wide spontaneous ADR reports sent from health care professionals to the respective national drug regulatory authority. In Spain, cases were recruited both from spontaneous ADR reports and through active surveillance at 17 hospitals in Barcelona.
German cases were recruited through active surveillance at 50 hospitals in Berlin as described. 11 No extra blood sampling or investigation was undertaken for cases collected through active surveillance as compared to those collected through spontaneous reports.
Each included subject was at least 18 years of age and able to give informed consent.
Cases were patients who had developed an absolute neutrophil count <0•5*10 9 /L (<500/µL) during drug therapy or within seven days of stopping medication. Each case was required to exhibit complete recovery after cessation of the drug with an absolute neutrophil count >1•0*10 9 /L (>1000/µL) or a compatible bone marrow aspirate or biopsy. Causality assessment was according to the WHO standard algorithm. 12 Exclusion criteria were recent chemotherapy, radiation therapy within the last month, bone marrow transplantation, ongoing infection with Epstein-Barr virus, hepatitis A, HIV, CMV or parvovirus B19, sepsis, miliary tuberculosis, chronic neutropenia (congenital cyclic, idiopathic), immunosuppressive therapy with cytotoxic drugs, malignant infiltration of bone marrow, hematological diseases (e.g. myelodysplasia, aplastic anemia, pancytopenia, other blood dyscrasias, such as hemoglobin ≤100 g/L and platelets ≤100*10 9 /L), and systemic lupus erythematosus. There were no other restrictions relating to other drug treatments, primary diagnosis, or ancestry.
We collected clinical data (demographics, medical history, drug treatment history, laboratory data, and ancestry) through interviews using a standardized questionnaire, and by obtaining and reviewing medical records. At each center, cases were evaluated by at least one senior investigator, and a final adjudication of the complete dataset was performed by a specialist in hematology. DNA was extracted from peripheral venous blood. The total number of cases fulfilling all requirements was 234 (Sweden, 94; Spain, 66; Germany, 41; France, 33), and 39 of these cases were induced by antithyroid agents (Sweden, 25; Spain, 4; Germany, 6; France, 4).
Consenting population controls were available from Sweden, Spain and Germany. In total, 5170 controls (4891 unrelated individuals from the Swedish Twin Registry, 13 
Power calculation
Power calculations were made both for the total number of cases (Supplementary Figure S1A) , and for the subset attributed to antithyroid drugs (Supplementary Figure   S1B ). The power to detect an odds ratio (OR) ≥5 was 99% when using all 234 cases and 5100 controls with a minor allele frequency (MAF) of ≥5%. The power to detect an OR of ≥5 was 80% when using 39 cases and 5100 controls with MAF ≥20%. These calculations are based on a genome-wide significance level of 5x10 -8 , an ADR prevalence of 1% and an additive genetic model. 15 GWAS quality control (QC) and data management was performed using PLINK v1.9.
Genome-wide array data and analyses
The resulting merged data included 596010 SNPs on the autosomal chromosomes. Imputation of genotypes was performed using PhaseIT 16 and Impute v2. 17 The total number of SNPs after imputation was 9380034. In order to account for possible population stratification, principal component analysis (PCA) was performed (Supplementary Figure S2 ). Six genetic outliers were detected using PCA, all were cases (Supplementary Figure S3 ). These cases were not excluded from the data, however, sensitivity analyses were performed by reanalyzing each top hit with the six cases excluded. See supplementary methods for additional details on QC, PCA and imputation.
All genome-wide analyses were adjusted for sex and the first four genetic principal components from the PCA. SNP effects were modeled as additive. The conventional genome-wide significance threshold p<5*10 -8 was used to correct for multiple testing. 18 Results are presented as Manhattan plots and QQ-plots. When genome-wide significant signals were found, analyses were performed sequentially by adjusting for each genome-wide significant signal until no genome-wide signals were left. Due to the heterogeneity in the data, follow up analyses were performed stratified by country of inclusion and drug class. Logistic regression was used to estimate univariate and multiple models. In the case when a value of zero was present in one cell, OR and CI were estimated by adding 0•5 to all cells. The predictive ability of the univariate and multiple models was expressed as the C-statistic. Our definition of the optimal cutoff for deciding when to consider a patient for alternative treatment (using a prediction model) was the cutoff that maximized both sensitivity and specificity. Genome-wide analyses were performed using PLINK v1.9 and individual SNP analyses were performed using R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
HLA allele imputation
Imputation of two and four digit classical HLA alleles (n=180), amino acid residues and individual SNPs was performed on the non-imputed merged and quality controlled genome-wide data using the software SNP2HLA with a reference panel of 5225 individuals. 19 To avoid confounding by indication, top HLA signals were tested using a cohort of cases and controls matched for hyperthyroidism that was available from Sweden.
Results
Overall 243 cases were collected for the study. Nine were excluded after adjudication:
seven Swedish cases (6.9%; 3 due to exposure to chemotherapy, 1 due to negative rechallenge, 2 due to unknown white blood cell count, 1 due to a diagnosis of chronic lymphatic leukaemia) and two Spanish cases (2.9%; both due to missing clinical data).
No German or French cases were excluded. Characteristics of all included cases are shown in Table 1 . Among them, 39 cases were induced by the antithyroid agents thiamazole (n=29), carbimazole (n=5), and propylthiouracil (n=5). Six of the 234 cases, including one case induced by antithyroid agents, were of non-Caucasian origin (Supplementary Figure S3 ).
Genome-wide association analyses -overall results
In the complete cohort of 234 cases and 5170 controls, we found genome-wide Figure S5 ) showed a similar pattern in Sweden, Germany and Spain. Cases from France were not tested separately due to lack of French controls.
Genome-wide association analyses by drug class
Stratification by the main drug classes revealed that the associations on chromosome 6 were largely driven by the 39 cases induced by antithyroid agents ( Figure 2B ). The associations were similar when the 5 cases on propylthiouracil were excluded (data not shown). The top SNP for cases induced by all antithyroid agents was rs652888 located in an intron of euchromatic histone-lysine N-methyltransferase 2 (EHMT2), OR Supplementary Table S2 ).
The estimated univariate ORs for the chromosome 6 associations in the overall analysis (rs114291795 and rs1811197) as well as for the top signals in cases induced by antithyroid agents (rs652888, rs199564443 and rs1071816) are shown in Figure 3A Figure S6) .
Analysis of four digit classical HLA alleles -overall results
After imputation of four digit HLA alleles, the respective univariate OR, 95% CI, and pvalue was calculated for each HLA allele vs the outcome agranulocytosis ( Table 2-III,   Supplementary Table S3 and Supplementary Figure S7 
Analysis of four digit classical HLA alleles by drug class
Drug-specific analysis showed that the overall association with HLA-B*27:05 was driven by agranulocytosis induced by antithyroid agents. The univariate OR for carrying HLA-B*27:05 was 5•44 among these cases (95% CI [2•94, 10•06] p=6•88*10 -8 , Table 2- IV, Supplementary Table S5 ). The top HLA imputed variant, rs652888, was the same SNP as in the genome-wide SNP analysis (Supplementary Figure S8A Supplementary Table S4 ).
Multiple models of four digit classical HLA alleles
Multiple regression models including HLA-B*27:05 and HLA-B*08:01 were compared between all cases and subsets of cases ( Figure 3B Figure S9) . Figure 3B ).
Predictive ability and clinical implications for cases induced by antithyroid agents
The optimal cutoff for deciding when to consider a patient for alternative treatment was at a predicted probability of 0•005. This gives an estimated sensitivity of 84•2% and a specificity of 86•1%, which means that 13•9% would be falsely predicted to be cases (Supplementary Figure S10) . In terms of individual SNPs, being heterozygous for only rs652888 or rs1071816 does not give a predicted probability above this cutoff, however all other combinations give predictions above 0•005 ( Figure 4 ). Assuming an incidence of antithyroid-induced agranulocytosis of 0•005 (1 in 200 patients starting antithyroid agents) 4 and a sensitivity of 84•2%, we could theoretically reduce the incidence to 0•00079 (0•005-0•842*0005). The number needed to genotype (NNG) to avoid one case of antithyroid-induced agranulocytosis was estimated to 238, which is the reciprocal of the absolute risk reduction, i.e. 1/(0•005-0•00079).
Discussion
In our GWAS, drug-induced agranulocytosis was associated with the HLA region on chromosome 6. Our finding adds to the growing number of drug-induced type B reactions associated with the HLA region, including Stevens-Johnson syndrome, druginduced liver injury and clozapine-induced agranulocytosis. 20 The HLA region is challenging to study due to high gene density, 21 high degree of polymorphism 22 and an extended LD that makes the causative variant difficult to identify. 21 Genetic susceptibility traits for rare serious ADRs are drug specific, as previously shown in genome-wide studies on drug-induced liver injury. 20 Overall, drug-induced agranulocytosis was associated with HLA-B*27:05. HLA-B*27:05 has previously been associated with agranulocytosis induced by another azole drug, levamisole. 23 In our cohort, no other single drug class apart from antithyroid agents was significantly associated with HLA-B*27:05. The association with HLA-B*27:05 was unchanged when cases induced by the antithyroid propylthiouracil were removed. The indication for antithyroid treatment is most commonly Graves' disease, an autoimmune disease that causes hyperthyroidism. 24 As Graves' disease per se has been associated with certain HLA types in Caucasians, in particular HLA-C*07 and HLA-B*08, 25 In our study, interesting genome-wide significant associations were also observed between antithyroid drug-induced agranulocytosis and the EHMT2 and FOXF2 genes.
Although we found associations between antithyroid drug-induced agranulocytosis and classical HLA alleles, we cannot exclude that nearby regulatory variants are the genuine causative factors. The lead SNP, i.e. rs652888, is intronic in EHMT2 that encodes the transcriptional repressor G9a, while rs199564443 is located in the promoter and rs115308096 in intron one of FOXF2 close to regulatory elements.
FOXF2 is a transcription factor expressed in many cells including lymph nodes. The predictive ability of our model increased when rs652888 and rs199564443 (alternatively rs115308096 which is easier to genotype) were used in combination with the HLA-B marker rs1071816. For instance, heterozygosity for all three SNPs increased the risk of agranulocytosis to 30% and the estimated OR to 753. In comparison, homozygosity for HLA-B*27:05 was associated with an estimated OR of 53, which suggests an added value of SNPs in genes involved in transcriptional regulation.
There are limitations of this study. First, the small sample size decreased the power to detect uncommon variants associated with the reaction. To alleviate this we could have actively recruited matched controls, but to find more cases of antithyroid druginduced agranulocytosis would have been difficult. Second, HLA imputation was used instead of direct HLA genotyping. The quality of imputed HLA variants are highly dependent on the reference panel, which in our study was 5225 European individuals from the Type 1 Diabetes Genetics Consortium (T1DGC). 19 These individuals had been recruited in Great Britain by the Wellcome Trust Case Control Consortium, and the vast majority were self-identified white Europeans. 28 Using the T1DGC reference panel, the imputation at four-digit resolution was shown to be accurate (96•7%) in the British 1958 Birth Cohort (n=918). However, there are errors even in established methods for HLA typing that may have limited the evaluation of accuracy. 22 An additional impediment was that our cohort is from four countries across Europe, but since the majority is Northern European, we believe the T1DGC reference panel to be representative for our HLA imputation.
In conclusion, we have shown that drug-induced agranulocytosis in people of European ancestry, particularly when induced by antithyroid agents, is associated with HLA-B*27:05 and with nearby genes. These are not the same risk markers as reported in ethnic Chinese. 8, 9 Both patient ethnicity and genotype should therefore be taken into consideration before starting antithyroid treatment. It has been predicted that in the future everyone will have the pharmacogenome in their medical record. 29 We advocate that Europeans known to carry combinations of HLA-B*27:05 or rs652888, rs199564443 and rs1071816 are offered an alternative treatment for hyperthyroidism, such as radioiodine or surgery. 30 How to use the nomogram: Find the points each genotype renders in the top axis "Points", and plot the total sum on the axis "Total Points" which will show the predicted probability of agranulocytosis.
Examples: Heterozygosity for rs622888 (i.e. 1 minor allele G) and no other variants gives a sum of 4•2, which is below the threshold 0•005 on the "Total Points" axis.
Heterozygosity for rs1071816 (i.e. 1 minor allele C) and no other variants gives a sum of 5, which is just at the threshold 0•005. All other possible combinations of variants are clearly above the threshold and indicate an increased risk of agranulocytosis.
Heterozygosity for rs199564443 (i.e. deletion of TTTT) and no other variants gives 8•6
points and a predicted probability of ~0•15, heterozygosity for rs622888 and rs1071816 gives a total of 9•2 points and a predicted probability of ~0•02, heterozygosity for rs199564443 and rs622888 and rs1071816 gives a total of 17•8 points and a predicted probability of ~0•30, homozygosity for rs622888 and rs1071816
gives a total of 18•4 points and a predicted probability of ~ 0•35. In theory, heterozygosity for rs199564443 and homozygosity for rs622888 and rs1071816 would give a total of 28•5 points and a predicted probability of close to 1. 
